Now, researchers at Columbia University have uncovered a biological mechanism that could help explain this remarkable resistance. Their findings point to a rare genetic mutation that protects the brain’s blood vessels from damage, potentially opening a new path toward Alzheimer’s treatments.

The discovery builds on research the team published two years ago involving APOE ε4, a gene variant strongly associated with Alzheimer’s risk. The scientists found that some people carrying APOE ε4 also possess a rare protective mutation in the fibronectin (FN1) gene.

Fibronectin is a protein that helps support the structure of tissues. However, in people with APOE ε4, excessive amounts can accumulate around blood vessels in the brain, potentially compromising a critical protective system known as the blood-brain barrier. The rare FN1 mutation appears to limit this buildup and the damage associated with it.

That earlier discovery suggested an intriguing possibility: What if scientists could develop a treatment that recreates the protection provided by this rare mutation?

A new study published in Nature Aging brings that possibility closer by identifying how excess fibronectin damages the brain’s protective barrier and revealing potential ways to interrupt the process.

“This new study takes us from a genetic clue to a disease mechanism,” says Caghan Kizil, the study’s corresponding author and professor of neurological sciences in the Department of Neurology and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain at Columbia University Vagelos College of Physicians and Surgeons.

“We knew that changes in fibronectin could protect against Alzheimer’s, but we didn’t know why excess fibronectin was harmful in the first place. This study gives us that detailed mechanism — and with it, ideas for how to reproduce that natural protection.”

How an Alzheimer’s Risk Gene Weakens the Blood-Brain Barrier

The blood-brain barrier serves as a protective boundary between the bloodstream and the brain. Made up of tightly connected cells surrounding the brain’s blood vessels, it carefully regulates which substances can enter brain tissue while helping maintain conditions necessary for removing potentially harmful waste.

When this barrier becomes damaged or excessively permeable, substances that would normally be kept out can enter the brain more easily. Such disruptions may contribute to inflammation and other processes involved in neurological diseases, including Alzheimer’s.

To investigate the role of fibronectin, the Columbia team combined several advanced research approaches. They examined human brain tissue and cerebrospinal fluid, the clear liquid surrounding the brain and spinal cord, using genetic and epigenetic analyses to explore changes in DNA and gene activity.

Their investigation also included single-cell sequencing, which reveals the activity of individual cells, and spatial imaging to examine where biological changes occur within tissues. Additional experiments involved human stem-cell models, three-dimensional cultures of blood vessels, and studies in zebrafish and mice.

Despite the variety of methods, the findings consistently pointed to the same mechanism: APOE ε4 promotes the production and accumulation of fibronectin around the brain’s blood vessels.

In mice engineered to carry human APOE ε4, researchers measured nearly twice as much fibronectin in the brain as in mice carrying APOE ε3, another common version of the gene. The greater accumulation was accompanied by evidence that the blood-brain barrier had become leaky.

Scientists Discover How Fibronectin Causes Brain Damage

One experiment provided especially important evidence that fibronectin does more than simply accumulate in damaged blood vessels.

The researchers increased human fibronectin specifically in astrocytes, specialized support cells that help maintain the blood-brain barrier and keep the brain functioning properly.

Increasing fibronectin in these cells was enough to disrupt the barrier, allowing it to become more permeable. Conversely, reducing fibronectin improved the barrier’s ability to function normally.

These results provided experimental evidence that excess fibronectin can directly contribute to blood-brain barrier damage rather than merely appearing alongside it.

“The animal experiments allowed us to move beyond association,” says co-first author Prabesh Bhattarai, an associate research scientist in the Kizil lab. “When we increased fibronectin in astroglia, the barrier became permeable. When we reduced fibronectin, barrier function improved.”

The team then investigated the molecular events responsible for the damage.

They found that excessive fibronectin interferes with communication between cells by activating abnormal signals through integrins, proteins that help cells sense and respond to their surroundings, and an enzyme known as focal adhesion kinase.

These abnormal signals disrupt a network of growth factors called VEGF, HBEGF, and IGF1. Although growth factors are often associated with cell development and repair, these particular signaling molecules also help astrocytes and blood vessel cells coordinate their activities to maintain a healthy blood-brain barrier.

When their communication becomes disrupted, the barrier can lose its integrity, potentially leaving brain tissue more vulnerable to damage.

“Single-cell analysis allowed us to examine this pathway in the different cells that maintain the brain’s blood vessels,” says co-first author Elanur Yilmaz, an associate research scientist in the Kizil lab. “We observed the same biological pattern across experimental models and human Alzheimer’s tissue, making the mechanism especially compelling.”

Evidence From Human Brains Strengthens the Alzheimer’s Connection

Importantly, the researchers found signs of similar biological disturbances in human samples, suggesting that the process identified in laboratory experiments may also contribute to Alzheimer’s disease in people carrying APOE ε4.

Analyses of brain tissue and cerebrospinal fluid showed that elevated fibronectin levels were associated with inflammation in astrocytes.

Genetic and gene-regulation analyses also connected FN1 to blood vessel disease and changes involving VEGFA, a growth factor that plays an important role in maintaining healthy brain blood vessels.

Together, these findings provide multiple lines of evidence linking excess fibronectin to the vascular damage associated with APOE ε4.

“The convergence of these independent human datasets strengthens the case that fibronectin is part of the APOE ε4-related vascular disease process,” says Badri Vardarajan, associate professor of neurological science in the Department of Neurology, Gertrude H. Sergievsky Center, and Taub Institute, who collaborated on this discovery of the FN1 mutation.

A Rare Genetic Defense Could Inspire New Alzheimer’s Treatments

The potential implications are significant because APOE ε4 is the strongest common genetic risk factor for Alzheimer’s disease. Approximately one in five people carries at least one copy of this gene variant.

Although carrying APOE ε4 does not guarantee that someone will develop Alzheimer’s, it increases their likelihood of developing the disease. Understanding why certain carriers remain unaffected could reveal new opportunities for prevention and treatment.

The latest findings suggest several possible approaches.

One strategy would be to prevent harmful amounts of fibronectin from accumulating around the brain’s blood vessels. Another would involve blocking the abnormal cellular signals triggered by excess fibronectin. A third possibility would be to restore the growth factor signaling that allows astrocytes and blood vessel cells to maintain the blood-brain barrier.

Researchers are already investigating these possibilities through laboratory experiments.

However, translating the discovery into a treatment will require considerable care. Fibronectin performs essential functions throughout the body, including supporting tissue structure and helping damaged tissues heal. Any future therapy would therefore need to target its harmful accumulation or effects without disrupting these beneficial activities.

By identifying the molecular mechanisms involved, scientists now have a more precise framework for designing such treatments. The findings may also help researchers determine when interventions would be most effective and how to measure whether they are successfully protecting the brain.

“By showing how fibronectin contributes to early vascular damage, this study gives us new therapeutic targets and potential ways to measure whether treatments are working,” says Richard Mayeux, chair of the Department of Neurology and a collaborator on the project. “Clinically, it connects a major genetic risk factor for Alzheimer’s to an early disease process that may be possible to modify.”

Although these potential therapies remain experimental, the discovery offers a promising new direction in Alzheimer’s research. Rather than focusing only on the damage that develops as the disease progresses, scientists may eventually be able to reproduce a natural genetic defense that helps protect vulnerable brains before significant damage occurs.